Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

FDA approves Watson Pharmaceuticals' twice-yearly Trelstar formulation for prostate cancer

March 15, 2010

FDA accepts for review Abbott's Lupron sNDA for prostate cancer

March 15, 2010

Pfizer discontinues phase III trial of figitumumab in NSCLC

March 15, 2010

French scientists claim epipodophyllotoxin derivatives with antitumor activity

March 15, 2010

Astex and Novartis claim the discovery of novel CDK4 inhibitors

March 12, 2010

Hedgehog pathway antagonist GDC-0449 shows clinical promise in metastatic basal cell carcinoma

March 12, 2010

AstraZeneca discloses novel JAK2 inhibitors for cancer therapy

March 11, 2010

Ark withdraws Cerepro MAA after EMA's request for further trial in malignant glioma

March 10, 2010

FDA and EMA grant orphan drug status to ImmunoGen's IMGN-901 in MCC

March 9, 2010

Nektar Therapeutics presents phase II data on NKTR-102 in platinum-resistant ovarian cancer

March 9, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...